Financial Intelligence
Scored 8/30/2026
Buffett Quality
3.0/10
Lynch Category
Fast Grower
Margin of Safety
—
Acquisition Risk
Not flagged
Owner Earnings
$495M
Recent Signals
20 foundALNYLAM PHARMACEUTICALS, INC.
source: edgar_efts · fund_count: 1 · fund_names: GraniteShares Advisors LLC
8/4/2026
55%
ALNYLAM PHARMACEUTICALS, INC.
news_score: null · bearish_pct: null · bullish_pct: null
7/30/2026
30%
ALNYLAM PHARMACEUTICALS, INC.
source: edgar_efts · fund_count: 2 · fund_names: Invesco Ltd.
7/15/2026
65%
ALNYLAM PHARMACEUTICALS, INC.
is_buy: false · shares: 495 · filing_date: 2026-06-03
6/3/2026
50%
ALNYLAM PHARMACEUTICALS, INC.
is_buy: false · shares: 921 · filing_date: 2026-06-03
6/3/2026
50%
ALNYLAM PHARMACEUTICALS, INC.
is_buy: false · shares: 1175 · filing_date: 2026-06-03
6/3/2026
50%
ALNYLAM PHARMACEUTICALS, INC.
is_buy: false · shares: 1222 · filing_date: 2026-06-03
6/3/2026
50%
ALNYLAM PHARMACEUTICALS, INC.
role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements
12/3/2025
45%
ALNYLAM PHARMACEUTICALS, INC.
role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements
12/3/2025
45%
ALNYLAM PHARMACEUTICALS, INC.
role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements
12/3/2025
45%
ALNYLAM PHARMACEUTICALS, INC.
role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements
12/3/2025
45%
ALNYLAM PHARMACEUTICALS, INC.
role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements
12/3/2025
45%
ALNYLAM PHARMACEUTICALS, INC.
role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements
1/4/2022
45%
ALNYLAM PHARMACEUTICALS, INC.
role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements
1/4/2022
45%
ALNYLAM PHARMACEUTICALS, INC.
role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements
1/4/2022
45%
ALNYLAM PHARMACEUTICALS, INC.
role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements
1/4/2022
45%
ALNYLAM PHARMACEUTICALS, INC.
role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements
1/4/2022
45%
ALNYLAM PHARMACEUTICALS, INC.
role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements
8/6/2020
45%
ALNYLAM PHARMACEUTICALS, INC.
role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements
8/6/2020
45%
ALNYLAM PHARMACEUTICALS, INC.
role: Executive · event_type: appointment · interpretation: C-suite appointment — monitor for subsequent strategic announcements
8/6/2020
45%
Watch Reason
S&P 500 / major index component — seeded via EDGAR